
    
      Participants who previously participated in Study JEC12 (NCT01396512) and were primed with
      IMOJEV received a booster dose of IMOJEV at least 12 months after the primary dose.
      Participants were assessed for immune response before and on Day 28 after the booster dose
      and were monitored for safety through Day 28 post-vaccination for non-serious adverse events
      (AEs) and up to 6 months post-vaccination for serious AEs The duration of each participant's
      participation in the study was approximately 6 months.
    
  